Reduced expression of peroxisome-proliferator activated receptor gamma coactivator-1α enhances α-synuclein oligomerization and down regulates AKT/GSK3β signaling pathway in human neuronal cells that inducibly express α-synuclein

Neuroscience Letters

Volumn 473, Issue 2, 2010, Pages 120-125

  Ebrahim, Abdul Shukkur ^a   Ko, Li wen ^a   Yen, Shu Hui ^a  

^a MAYO GRADUATE SCHOOL   (United States)

Author keywords

Synuclein; Human neuroblastoma cells; Parkinson's disease; PGC 1

Indexed keywords

ALPHA SYNUCLEIN; GLYCOGEN SYNTHASE KINASE 3BETA; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROTEIN KINASE B; PROTEIN P53; SHORT HAIRPIN RNA; TETRACYCLINE;

ARTICLE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENERGY METABOLISM; HUMAN; HUMAN CELL; LEWY BODY; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; NEUROBLASTOMA CELL; NEUROTOXICITY; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN INDUCTION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; WILD TYPE;

ALPHA-SYNUCLEIN; BIOPOLYMERS; CELL LINE; DOWN-REGULATION; GENE KNOCKDOWN TECHNIQUES; GLYCOGEN SYNTHASE KINASE 3; HEAT-SHOCK PROTEINS; HUMANS; LEWY BODIES; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; NEURONS; ONCOGENE PROTEIN V-AKT; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 77949912389     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2010.02.034     Document Type: Article

References (25)

1. Alves Da Costa C., Paitel E., Vincent B., Checler F. Alpha-synuclein lowers p53-dependent apoptotic response of neuronal cells. Abolishment by 6-hydroxydopamine and implication for Parkinson's disease. J. Biol. Chem. 2002, 277:50980-50984.
2. Anderson R.M., Barger J.L., Edwards M.G., Braun K.H., O'Connor C.E., Prolla T.A., Weindruch R. Dynamic regulation of PGC-1alpha localization and turnover implicates mitochondrial adaptation in calorie restriction and the stress response. Aging Cell. 2008, 7:7101-7111.
3. Betarbet R., Canet-Aviles R.M., Sherer T.B., Mastroberardino P.G., McLendon C., Kim J.H., Lund S., Na H.M., Taylor G., Bence N.F., Kopito R., Seo B.B., Yagi T., Yagi A., Klinefelter G., Cookson M.R., Greenamyre J.T. Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol. Dis. 2006, 22:404-420.
4. Borland M.K., Mohanakumar K.P., Rubinstein J.D., Keeney P.M., Xie J., Capaldi R., Dunham L.D., Trimmer P.A., Bennett J.P. Relationships among molecular genetic and respiratory properties of Parkinson's disease cybrid cells show similarities to Parkinson's brain tissues. Biochim. Biophys. Acta 2009, 1792:68-74.
5. Clark J., Simon D.K. Transcribe to Survive: transcriptional control of antioxidant defense programs for neuroprotection in Parkinson's disease. Antioxid. Redox Signal. 2009, 11:509-528.
6. Cui L., Jeong H., Borovecki F., Parkhurst C.N., Tanese N., Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006, 127:59-69.
7. Duka T., Duka V., Joyce J.N., Sidhu A. Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models. FASEB J. 2009, 23:2820-2830.
8. Esposito A., Dohm C.P., Kermer P., Bahr M., Wouters F.S. Alpha-synuclein and its disease-related mutants interact differentially with microtubule protein tau and associate with the actin cytoskeleton. Neurobiol. Dis. 2007, 26:521-531.
9. Hsu L.J., Sagara Y., Arroyo A., Rockenstein E., Sisk A., Mallory M., Wong J., Takenouchi T., Hashimoto M., Masliah E. α-Synuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol. 2000, 157:401-410.
10. Ko L.W., Ko H.H., Lin W.L., Kulathingal J.G., Yen S.H. Aggregates assembled from overexpression of wild-type alpha-synuclein are not toxic to human neuronal cells. J. Neuropathol. Exp. Neurol. 2008, 67:1084-1096.
11. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., Messadeq N., Milne J., Lambert P., Elliott P., Geny B., Laakso M., Puigserver P., Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006, 127:1109-1122.
12. Lee D.W., Rajagopalan S., Siddiq A., Gwiazda R., Yang L., Beal M.F., Ratan R.R., Andersen J.K. Inhibition of prolyl hydroxylase protects against MPTP-induced neurotoxicity: model for the potential involvement of the hypoxia-inducible factor pathway in Parkinson's disease. J. Biol. Chem. 2009, 284:29065-29076.
13. Lehman J.J., Barger P.M., Kovacs A., Saffitz J.E., Medeiros D.M., Kelly D.P. Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. J. Clin. Invest. 2000, 106:847-856.
14. Lin M.T., Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443:787-795.
15. Lin J., Wu P.H., Tarr P.T., Lindenberg K.S., St-Pierre J., Zhang C.Y., Mootha V.K., Jäger S., Vianna C.R., Reznick R.M., Cui L., Manieri M., Donovan M.X., Wu Z., Cooper M.P., Fan M.C., Rohas L.M., Zavacki A.M., Cinti S., Shulman G.I., Lowell B.B., Krainc D., Spiegelman B.M. Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell 2004, 119:121-135.
16. Sherer T.B., Betarbet R., Testa C.M., Seo B.B., Richardson J.R., Kim J.H., Miller G.W., Yagi T., Matsuno-Yagi A., Greenamyre J.T. Mechanism of toxicity in rotenone models of Parkinson's disease. J. Neurosci. 2003, 23:10756-10764.
17. Sherer T.B., Betarbet R., Stout A.K., Lund S., Baptista M., Panov A.V., Cookson M.R., Greenamyre J.T. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J. Neurosci. 2002, 22:7006-7015.
18. Sousa V.L., Bellani S., Giannandrea M., Yousuf M., Valtorta F., Meldolesi J., Chieregatti E. Alpha-synuclein and its A30P mutant affect actin cytoskeletal structure and dynamics. Mol. Biol. Cell. 2009, 20:3725-3739.
19. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. α-synuclein in Lewy bodies. Nature 1997, 388:839-840.
20. St-Pierre J., Drori S., Uldry M., Silvaggi J.M., Rhee J., Jäger S., Handschin C., Zheng K., Lin J., Yang W., Simon D.K., Bachoo R., Spiegelman B.M. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 2006, 127:397-408.
21. Trimmer P.A., Bennett J.P. The cybrid model of sporadic Parkinson's disease. Exp. Neurol. 2009, 218:320-325.
22. Valle I., Alvarez-Barrientos A., Arza E., Lamas S., Monsalve M. PGC-1alpha regulates the mitochondrial antioxidant defense system in vascular endothelial cells. Cardiovasc. Res. 2005, 66:562-573.
23. Wooten G.F. Neurochemistry and neuropharmacology of Parkinson's disease. Movement Disorders: Neurologic Principles and Practice 1997, 153-160. R.L. Watts, W.C. Koller (Eds.).
24. Yuan Y., Jin J., Yang B., Zhang W., Hu J., Zhang Y., Chen N.H. Overexpressed alpha-synuclein regulated the nuclear factor-kappaB signal pathway. Cell Mol. Neurobiol. 2008, 28:21-33.
25. Zhang D., Anantharam V., Kanthasamy A., Kanthasamy A.G. Neuroprotective effect of protein kinase C delta inhibitor rottlerin in cell culture and animal models of Parkinson's disease. J. Pharmacol. Exp. Ther. 2007, 322:913-922.